{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:52:00Z","timestamp":1791395520557,"version":"4.3.3"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICI) have provided significant improvement in clinical outcomes for some patients with solid tumors. However, for patients with head and neck cancer, the response rate to ICI monotherapy remains low, leading to the exploration of combinatorial treatment strategies. In this preclinical study, we use an oncolytic adenovirus (Ad5\/3) encoding hTNF\u03b1 and hIL-2 and non-replicate adenoviruses (Ad5) encoding mTNF\u03b1 and mIL-2 with ICI to achieve superior tumor growth control and improved survival outcomes. The <jats:italic>in vitro<\/jats:italic> effect of Ad5\/3-E2F-D24-hTNFa-IRES-hIL-2 was characterized through analyses of virus replication, transgene expression and lytic activity using head and neck cancer patient derived cell lines. Mouse models of ICI na\u00efve and refractory oral cavity squamous cell carcinoma were established to evaluate the local and systemic anti-tumor immune response upon ICI treatment with or without the non-replicative adenovirus encoding mTNF\u03b1 and mIL-2. We delineated the mechanism of action by measuring the metabolic activity and effector function of CD3<jats:sup>+<\/jats:sup> tumor infiltrating lymphocytes (TIL) and transcriptomic profile of the CD45<jats:sup>+<\/jats:sup> tumor immune compartment. Ad5\/3-E2F-D24-hTNFa-IRES-hIL-2 demonstrated robust replicative capability <jats:italic>in vitro<\/jats:italic> across all head and neck cell lines screened through potent lytic activity, E1a and transgene expression. <jats:italic>In vivo<\/jats:italic>, in both ICI na\u00efve and refractory models, we observed improvement to tumor growth control and long-term survival when combining anti-PD-1 or anti-PD-L1 with the non-replicative adenovirus encoding mTNF\u03b1 and mIL-2 compared to monotherapies. This observation was verified by striking CD3<jats:sup>+<\/jats:sup> TIL derived mGranzyme b and interferon gamma production complemented by increased T cell bioenergetics. Notably, interrogation of the tumor immune transcriptome revealed the upregulation of a gene signature distinctive of tertiary lymphoid structure formation upon treatment of murine anti-PD-L1 refractory tumors with non-replicative adenovirus encoding mTNF\u03b1 and mIL-2. In addition, we detected an increase in anti-tumor antibody production and expansion of the memory T cell compartment in the secondary lymphoid organs. In summary, a non-replicative adenovirus encoding mTNF\u03b1 and mIL-2 potentiates ICI therapy, demonstrated by improved tumor growth control and survival in head and neck tumor-bearing mice. Moreover, the data reveals a potential approach for inducing tertiary lymphoid structure formation. Altogether our results support the clinical potential of combining this adenovirotherapy with anti-PD-1 or anti-PD-L1.<\/jats:p>","DOI":"10.3389\/fimmu.2022.794251","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T07:30:05Z","timestamp":1646638205000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"James H. A.","family":"Clubb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Kudling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Heini\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saru","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santeri","family":"Pakola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Cervera Carrasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Manuel","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafne C. A.","family":"Quixabeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Sorsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuula","family":"Salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"B\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katri","family":"Aro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanni","family":"Tulokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venla","family":"Loimu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937","article-title":"Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer Statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA: A Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy Plus Cetuximab or Cisplatin in Human Papillomavirus-Positive Oropharyngeal Cancer (NRG Oncology RTOG 1016): A Randomised, Multicentre, Non-Inferiority Trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.oraloncology.2018.02.017","article-title":"Upfront Surgery Versus Definitive Chemoradiotherapy in Patients With Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer","volume":"79","author":"Kelly","year":"2018","journal-title":"Oral Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2018.08.001","article-title":"Patterns of Failure in High-Metastatic Node Number Human Papillomavirus-Positive Oropharyngeal Carcinoma","volume":"85","author":"Lee","year":"2018","journal-title":"Oral Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"55600","DOI":"10.18632\/oncotarget.16340","article-title":"Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma: Incidence, Survival, Prognostic Factors, and Treatment Outcomes","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0347(200010)22:7<680::aid-hed7>3.0.co;2-j","article-title":"Distant Metastases in Head and Neck Cancer Patients Who Achieved Loco-Regional Control","volume":"22","author":"Leon","year":"2000","journal-title":"Head Neck"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01721","article-title":"The Evolving Landscape of PD-1\/PD-L1 Pathway in Head and Neck Cancer","volume":"11","author":"Qiao","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression During Anti-PD-1\/PD-L1 Therapy in Patients With Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of Resistance to Immune Checkpoint Inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131242","article-title":"Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors","volume":"10","author":"T\u00e4htinen","year":"2015","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.10.013","article-title":"Opposing Development of Cytotoxic and Follicular Helper CD4 T Cells Controlled by the TCF-1-Bcl6 Nexus","volume":"17","author":"Donnarumma","year":"2016","journal-title":"Cell Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed With Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol Ther - Oncolytics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.137","article-title":"Adenoviral Delivery of Tumor Necrosis Factor-\u03b1 and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma","volume":"24","author":"Siurala","year":"2016","journal-title":"Mol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/cells9040798","article-title":"Tnf\u03b1 and IL-2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling","volume":"9","author":"Heini\u00f6","year":"2020","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000188","article-title":"Oncolytic Adenovirus Shapes the Ovarian Tumor Microenvironment for Potent Tumor-Infiltrating Lymphocyte Tumor Reactivity","volume":"8","author":"Santos","year":"2020","journal-title":"J ImmunoTherapy Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0220-T","article-title":"Adenovirus Improves the Efficacy of Adoptive T-Cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor","volume":"3","author":"T\u00e4htinen","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1412902","DOI":"10.1080\/2162402X.2017.1412902","article-title":"Tnf\u03b1 and IL-2 Armed Adenoviruses Enable Complete Responses by Anti-PD-1 Checkpoint Blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"OncoImmunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1761229","DOI":"10.1080\/2162402X.2020.1761229","article-title":"Tumor Microenvironment Remodeling by an Engineered Oncolytic Adenovirus Results in Improved Outcome From PD-L1 Inhibition","volume":"9","author":"Cervera-Carrascon","year":"2020","journal-title":"OncoImmunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S","article-title":"In Vitro Radiation Resistance Among Cell Lines Established From Patients With Squamous Cell Carcinoma of the Head and Neck","volume":"67","author":"Gr\u00e9nman","year":"1991","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0733","article-title":"Drug-Sensitivity Screening and Genomic Characterization of 45 hpV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy","volume":"17","author":"Lepikhova","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23967","article-title":"Interleukin 8 Activity Influences the Efficacy of Adenoviral Oncolytic Immunotherapy in Cancer Patients","volume":"9","author":"Taipale","year":"2018","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"p.246","DOI":"10.3390\/cells10020246","article-title":"Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination With Immune Checkpoint Inhibitor Anti-PD-1","volume":"10","author":"Havunen","year":"2021","journal-title":"Cells"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of Virus-Mediated Immunogenic Cancer Cell Death and the Consequences for Oncolytic Virus-Based Immunotherapy of Cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-23355-x","article-title":"B Cell Signatures and Tertiary Lymphoid Structures Contribute to Outcome in Head and Neck Squamous Cell Carcinoma","volume":"12","author":"Ruffin","year":"2021","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2931-3","article-title":"Defining HPV-Specific B Cell Responses in Patients With Head and Neck Cancer","volume":"597","author":"Wieland","year":"2021","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.11.014","article-title":"Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer","volume":"52","author":"Cillo","year":"2020","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6890-14-38","article-title":"Characterisation and Prognostic Value of Tertiary Lymphoid Structures in Oral Squamous Cell Carcinoma","volume":"14","author":"Wirsing","year":"2014","journal-title":"BMC Clin Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001187","article-title":"A New Role for Circulating T Follicular Helper Cells in Humoral Response to Anti-PD-1 Therapy","volume":"8","author":"S\u00e1nchez-Alonso","year":"2020","journal-title":"J ImmunoTherapy Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.706517","article-title":"Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1","volume":"12","author":"Cervera-Carrascon","year":"2021","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000144","article-title":"T-Cell Therapy Enabling Adenoviruses Coding for IL-2 and Tnf\u03b1 Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma","volume":"39","author":"T\u00e4htinen","year":"2016","journal-title":"J Immunother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01475-7","article-title":"IL-2 Imprints Human Naive B Cell Fate Towards Plasma Cell Through ERK\/ELK1-Mediated BACH2 Repression","volume":"8","author":"Hipp","year":"2017","journal-title":"Nat Commun"},{"key":"B38","article-title":"Differential Activities of Secreted Lymphotoxin-\u03b13 and Membrane Lymphotoxin-\u03b11\u03b22 in Lymphotoxin-Induced Inflammation: Critical Role of TNF Receptor 1 Signaling","volume":"160","author":"Rosalba","year":"1998","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.02.017","article-title":"Critical Role of STAT5 Transcription Factor Tetramerization for Cytokine Responses and Normal Immune Function","volume":"36","author":"Lin","year":"2012","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091472","article-title":"Induced Bronchus-Associated Lymphoid Tissue Serves as a General Priming Site for T Cells and is Maintained by Dendritic Cells","volume":"206","author":"Halle","year":"2009","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3748\/wjg.v20.i3.684","article-title":"Role of Helicobacter Pylori in Gastric Mucosa-Associated Lymphoid Tissue Lymphomas","volume":"20","author":"Pereira","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/6.12.1883","article-title":"CD40 Ligation Induces Lymphotoxin \u03b1 Gene Expression in Human B Cells","volume":"6","author":"Worm","year":"1994","journal-title":"Int Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626776","article-title":"Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients","volume":"12","author":"Germain","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.91487","article-title":"CXCL13-Producing TFH Cells Link Immune Suppression and Adaptive Memory in Human Breast Cancer","volume":"2","author":"Gu-Trantien","year":"2017","journal-title":"JCI Insight"},{"key":"B45","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A Transcriptionally and Functionally Distinct PD-1+ CD8+ T Cell Pool With Predictive Potential in non-Small-Cell Lung Cancer Treated With PD-1 Blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0081","article-title":"A Strong B-Cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases","volume":"23","author":"Montfort","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305394110","article-title":"Strength of PD-1 Signaling Differentially Affects T-Cell Effector Functions","volume":"110","author":"Wei","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.immuni.2019.12.007","article-title":"Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells","volume":"52","author":"\u015aledzi\u0144ska","year":"2020","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071949","article-title":"Enhancing Therapeutic Vaccination by Blocking PD-1\u2013Mediated Inhibitory Signals During Chronic Infection","volume":"205","author":"Ha","year":"2008","journal-title":"J Exp Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1086\/513441","article-title":"Risk of Cervical Intraepithelial Neoplasia Grade 2 or 3 After Loop Electrosurgical Excision Procedure Associated With Human Papillomavirus Type 16 Variants","volume":"195","author":"Xi","year":"2007","journal-title":"J Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e2","article-title":"A Human Papillomavirus (HPV)-16 or HPV-18 Genotype is a Reliable Predictor of Residual Disease in a Subsequent Hysterectomy Following a Loop Electrosurgical Excision Procedure for Cervical Intraepithelial Neoplasia 3","volume":"27","author":"Kang","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1055-9965.EPI-05-0845","article-title":"Human Papillomavirus Testing Following Loop Electrosurgical Excision Procedure Identifies Women at Risk for Posttreatment Cervical Intraepithelial Neoplasia Grade 2 or 3 Disease","volume":"15","author":"Kreimer","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/1874357901206010241","article-title":"The Immune Response to Papillomavirus During Infection Persistence and Regression","volume":"6","author":"Hibma","year":"2012","journal-title":"Open Virol J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/bjc.2013.639","article-title":"Tumour-Infiltrating Lymphocytes Predict for Outcome in HPV-Positive Oropharyngeal Cancer","volume":"110","author":"Ward","year":"2014","journal-title":"Br J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100994108","article-title":"B Regulatory Cells and the Tumor-Promoting Actions of TNF- During Squamous Carcinogenesis","volume":"108","author":"Schioppa","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxv038","article-title":"The Expanding Family of Regulatory B Cells","volume":"27","author":"Mauri","year":"2015","journal-title":"Int Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1877","article-title":"PD-1 Regulates Germinal Center B Cell Survival and the Formation and Affinity of Long-Lived Plasma Cells","volume":"11","author":"Good-Jacobson","year":"2010","journal-title":"Nat Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"B Cells, Plasma Cells and Antibody Repertoires in the Tumour Microenvironment","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.794251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T07:30:15Z","timestamp":1646638215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.794251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2022.794251"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.794251","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"article-number":"794251"}}